Xeltis BV raised $15 million in series D2 funding to develop its restorative vascular access device for patients with chronic kidney disease who are on hemodialysis. The investment in this technology, called the Axess graft, came from Hong Kong-based China Grand Pharmaceutical and Healthcare Holdings Ltd. (Grand Pharma). The deal focuses mainly on commercializing Axess, but also involves other new products in the field of hemodialysis developed as part of the Xeltis technology platform. The commitment from Grand Pharma includes equity investment and product licensing, representing Xeltis’ first commercial deal and its first funding from an Asian concern.

Endometriosis affects one in 10 women, but diagnosis of this fertility impairing, and often painful condition often takes a decade. A growing number of companies hope to put women with the condition on the path to treatment much sooner with new diagnostics and investors, investigators and regulators see bright opportunities in the field.

Shanghai United Imaging Healthcare Co. Ltd. went public in the Shanghai Stock Exchange STAR Market and raised ¥11 billion (US$1.6 billion) in its initial public offering.

Antegenes OÜ raised $2.4 million in seed funding to deploy its genomic testing for personalized cancer prevention in new markets across Europe.

Nanjing Medlander Medical Technology Co. Ltd. raised ¥1.01 billion (US$148.8 million) with its initial public offering on the Shanghai STAR Market.